v3.25.4

Significant Transactions - AstralBio License Agreements (Details) - USD ($)	Apr. 21, 2025	Jan. 29, 2025	Jan. 28, 2025
Myostatin License Agreement
Significant Transactions
Payment of upfront licensing fee		$ 750,000	$ 750,000
Number of shares issued		246,087	246,087
Aggregate potential milestone payments payable in licensing agreement			$ 28,000,000
Equity ownership (ceiling)			19.90%
Activin E License Agreement
Significant Transactions
Payment of upfront licensing fee	$ 750,000
Aggregate potential milestone payments payable in licensing agreement	$ 28,000,000
Equity ownership (ceiling)	19.90%

The ceiling on stock ownership percentage in connection with milestone payments from licensing agreement settled in the form of the Company's common stock

+ References

No definition available.

+ Details

Name:	ibio_CeilingOnStockOwnershipPercentage
Namespace Prefix:	ibio_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Potential amount of contingent payments payable by the company upon achievement of specified milestones related to the Company's licensing agreement with AstralBio.

+ References

No definition available.

+ Details

Name:	ibio_PotentialContingentPaymentsRelatedToLicensingAgreement
Namespace Prefix:	ibio_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of cash outflow for fees classified as other.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (g)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-25

+ Details

Name:	us-gaap_PaymentsForFees
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.

+ References

No definition available.

+ Details

Name:	us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=ibio_ExclusiveLicenseAgreementWithAstralbioForMyostatinMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=ibio_ExclusiveLicenseAgreementWithAstralbioForActivinEMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

iBio, Inc. 10-Q